Anti-tumor activity of HER-specific peptide vaccines-CKL9 and YL20
10.3969/j.issn.1001-1978.2017.07.022
- VernacularTitle:针对HER-2的多肽疫苗CKL9与YL20的抗肿瘤活性研究
- Author:
Longguan CHEN
;
Yan SONG
;
Yuansheng XU
;
Yunna HUANG
;
Jinhong QIN
;
Qiuling XIE
- Keywords:
HER-2/neu;
peptide vaccination;
T-lymphocyte;
immune response;
N87;
anti-tumor
- From:
Chinese Pharmacological Bulletin
2017;33(7):997-1002
- CountryChina
- Language:Chinese
-
Abstract:
Aim To explore whether the polypeptide vaccines CKL9 and YL20 can induce immune response and anti-tumor effect on HER-2 (+) tumors in vitro and in vivo, and to provide suggestions for clinical use.Methods The proliferation of specific lymphocytes and cytotoxic T lymphocyte activity(CTL) stimulated by CKL9 and YL20 were studied with CCK-8 assay and LDH assay, and the antitumor activity of CKL9 and YL20 was evaluated in vivo.Results The lymphocyte proliferation was promoted by incubation with CKL9 and YL20, and the relative increase of cells was 11.1% and 16.7% respectively at the concentration of 50 mg·L-1 of CKL9 and YL20.The LDH assay confirmed the CTL effect induced by CKL9 and YL20 on HER2-positive tumor cells, not on HER2-negtive tumor cells.With an effector-target ratio of 80 ∶1, the inhibition of tumor cell by cytotoxic T lymphocyte stimulated by CKL9 and YL20 could reach 89.8% and 84.3%, respectively.The HER2(+) tumor cell N87 transplanted in Babes mice was inhibited by pre-immune polypeptide CKL9 and YL20.Conclusion The HER2-specific polypeptide vaccines CKL9 and YL20 could induce persistent specific CD4 and CD8 T cell immune and inhibit the growth of HER2 positive tumor cells.
